| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cost of Revenue | $0 | — |
| R&D Expense | $16.0M | -16.1% |
| SG&A Expense | $12.3M | -1.3% |
| Operating Income | -$28.3M | +10.3% |
| Pre-tax Income | -$26.9M | +13.0% |
| Income Tax | $0 | — |
| Net Income | -$26.9M | +13.0% |
| EPS (Basic) | -$0.25 | +50.0% |
| EPS (Diluted) | -$0.25 | +50.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $71.8M | +417.0% |
| Current Assets | $75.2M | +360.7% |
| Total Assets | $78.3M | +303.2% |
| Current Liabilities | $7.0M | -26.2% |
| Total Liabilities | $7.5M | -25.0% |
| Stockholders' Equity | $70.9M | +648.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$28.4M | +19.8% |
| Financing Cash Flow | $86.3M | +84.6% |